Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen reports positive data from cholesterol drug trial

Amgen reports positive data from cholesterol drug trial

20th December 2013

Amgen has announced positive data from Mendel-2, a new phase III trial of its cholesterol reduction therapy evolocumab.

The drug was able to meet its co-primary endpoints in the study, showing a strong reduction in levels of low-density lipoprotein cholesterol (LDL-C) – sometimes known as "bad" cholesterol – after 12 weeks.

Evolocumab is an investigational fully-human monoclonal antibody that functions by inhibiting proprotein convertase subtilisin/kexin type 9, a protein that reduces the liver's ability to remove LDL-C from the blood.

This is the first study in the Proficio clinical trial programme, which will include a total of 13 trials and a combined planned enrollment of more than 28,000 patients.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "The positive results we have seen with two distinct dosing options suggest that evolocumab may offer a promising approach to treat patients with high cholesterol."

This comes after the company reported encouraging interim overall survival results from a study of its new melanoma drug talimogene laherparepvec last month.ADNFCR-8000103-ID-801674943-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.